Drugs / H1ssF_3928
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03814720 | Apr 2019 → Apr 2021 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H1ssF_3928 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03814720 ↗ |
| Known as | VRC-FLUNPF099-00-VP | “The investigational vaccine, VRC-FLUNPF099-00-VP (H1ssF\_3928), was developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID)” NCT03814720 ↗ |
| Modality | Vaccine | “The investigational vaccine” NCT03814720 ↗ |
| Route | Intramuscular | “H1ssF\_3928 was administered intramuscularly (IM) in the deltoid muscle via needle and syringe.” NCT03814720 ↗ |